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Daily Fluctuations of Progesterone and Testosterone
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Abstract: The purpose of this longitudinal blood sampling study was to examine relationships between
sex hormones and fibromyalgia pain. Eight women meeting case definition criteria for fibromyalgia
provided venous blood samples and reported their fibromyalgia pain severity over 25 consecutive
days. All women exhibited normal menstrual cycles and were not taking oral contraceptives. Corti-
sol, and the sex hormones estradiol, progesterone, and testosterone, were assayed from serum. A
linear mixed model was used to determine if fluctuations of sex hormones were associated with changes
in pain severity. In the entire sample, day to day changes in progesterone (P = .002) as well as tes-
tosterone (P = .015) were significantly and inversely correlated with pain severity. There was no
relationship between estradiol and pain (P = .551) or cortisol and pain (P = .633). These results suggest
that progesterone and testosterone play a protective role in fibromyalgia pain severity. Sex and other
hormones may serve to increase as well as decrease fibromyalgia pain severity.
Perspective: Sex hormones fluctuate normally in women with fibromyalgia, but may still contrib-
ute to pain severity.
© 2017 The Author(s). Published by Elsevier Inc. on behalf of the American Pain Society. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fibromyalgia, a chronic pain disorder of unknownetiology, disproportionately affects women overmen.49 The condition is characterized by diffuse mus-
culoskeletal pain, increased sensitivity to pressure at soft
tissues, profound fatigue, and self-reported cognitive
disruption.46 One notable feature of fibromyalgia is that
the symptom severity can vary markedly over short periods
of time, with severity on any particular day being largely
unpredictable.43 The lack of predictability adds to the de-
bilitating nature of the disorder, because planning future
activities can be difficult for sufferers.
The higher prevalence of fibromyalgia in women shows
biological sex to be an important consideration in the
disorder.30 There is, however, only limited evidence sup-
porting a link between sex hormones and fibromyalgia
incidence or severity. The incidence of pediatric
fibromyalgia has been shown to be similar in both genders
until the onset of puberty, when the incidence rate in-
creases in girls.26 In addition, it has been posited that the
sex hormone testosterone may provide a protective effect
against these types of chronic pain disorders,7 with trans-
dermal testosterone gel significantly reducing fibromyalgia
pain in women.45
There are several mechanisms by which sex hormones
could affect the experience of pain, which have been
covered extensively in recent review articles.34,41 These
mechanisms include effects on: peripheral nociceptors,17
central nociceptive processing,28 spinal inflammation,39
central microglia,35 affective brain systems that modu-
late pain,2,47 and opioid systems.25,40
Testosterone5 and progesterone8 are generally shown
to be associated with lower experience of pain. Proges-
terone in particular appears to have central anti-
inflammatory, neuroprotective, and analgesic effects.11,16,22
Progesterone may also have local effects as it has been
shown to be superior to corticosteroids in treating carpal
tunnel syndrome.32
Estradiol effects on nociception and pain are more
complex. Estradiol has been shown in many cases to be
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antinociceptive,12,44 as well as pronociceptive;20,31 the latter
effect being mediated partially by upregulation of
vanilloid-1 and anoctamin-1 in primary sensory neurons.48
It is likely that estradiol metabolites (estradiol-3-
glucuronide and estradiol-17-glucuronide) have complex
effects on pain.21 Also, specific estrogen receptor sub-
types may play different roles in the relative pro- and
antinociceptive properties of estrogen.9
To test if sex hormones affect fibromyalgia pain, we
conducted this daily sampling study in 8 normally-
cycling women with fibromyalgia. Sex hormones
(estradiol, progesterone, and testosterone) and self-
reported pain were assessed daily during the 25-day
protocol. We tested 3 specific hypotheses in this study:
first, progesterone would be negatively associated with
pain. Second, testosterone would be negatively associ-
ated with pain. Third, estradiol would be positively
associated with pain. Convincing cases for either a posi-
tive estradiol-pain relationship or negative relationship
could be made and supported by the literature. Al-
though we hypothesized a positive relationship between
estradiol and pain, all tests were conducted 2-tailed. In
addition, because previous literature has shown a posi-
tive relationship between cortisol levels and fibromyalgia
pain,15 we also assayed cortisol at all time points. To our
knowledge, this is the first study to use daily hormone
measurements to test the relationship between sex hor-
mones and fibromyalgia severity.
Methods
Participant Selection
All procedures were approved by the University of
Alabama at Birmingham (UAB) institutional review board.
This study was completed between June 2015 and Feb-
ruary 2017. Potential participants were identified via the
laboratory’s database of 1,200 local individuals who had
expressed an interest in research participation. Individu-
als from the online database were selected for an
additional phone screening if they were female, were
within 1 hour driving distance to the laboratory, were
between the ages of 18 and 65 years, met the Ameri-
can College of Rheumatology 2010 self-reported
fibromyalgia case definition criteria,46 and indicated an
average daily pain of at least 3 of 10. Pain was assessed
with a single item, “How would you rate your average
daily pain on a scale from 0 (no pain at all) to 10 (worst
possible pain).” Individuals did not pass the online screen-
ing stage if they indicated a diagnosis or medications for
any significant medical conditions (eg, cancer, heart
disease, diabetes, liver disease, neurological disorders, or
neurodegenerative diseases). Individuals were also not
considered if they indicated a diagnosis or medications
for any autoimmune or rheumatologic disorder.
Twenty individuals from the online database were con-
tacted via phone for a second screening, conducted by
a member of the research team. In the phone screen-
ing, individuals were excluded from participation if
they indicated any blood clotting disorders or other
contraindications for phlebotomy, or if reporting a hys-
terectomy, current pregnancy, or active plans to become
pregnant. Participants must also have indicated having
normal and predictable menstrual cycles. Medications
were reviewed and individuals were excluded if taking
blood thinning, anti-inflammatory, rheumatologic, an-
tibiotic, hormone-based contraceptive, opioid analgesic
medications, or any hormone therapies. During the phone
screening, the study was also described in depth and in-
dividuals were asked whether they were interested in
participating.
Nine women who passed the screenings and were in-
terested in participation were invited to a laboratory
screening session at the Clinical Research Unit at UAB.
At the screening visit, participants provided written, in-
formed consent and provided a blood sample for
screening tests. Participants were excluded from the study
if they had abnormal renal function, tri-iodothyronine,
thyroxine, thyroxin binding globulin, thyroid stimulat-
ing hormone, complete blood count with differential, or
25-hydroxy vitamin D. Participants were also excluded if
they presented with detectable rheumatoid factor or an-
tinuclear antibody, or had an erythrocyte sedimentation
rate >60 mm/h. All screening blood results were re-
viewed by Dr. Timothy Ness (UAB Department of
Anesthesiology and Perioperative Medicine).
During the screening visit, participants also com-
pleted several self-report questionnaires that were not
used in analyses, but instead used to capture additional
exclusionary criteria. Depressed mood and anxiety was
measured with the Hospital Anxiety and Depression
Scale.50 The depressed mood and anxiety subscales yield
possible scores of 0 to 7 (normal), 8 to 10 (mild), 11 to
14 (moderate), and 15 to 21 (severe), with scores >15 being
exclusionary. Pain severity was assessed with the Brief Pain
Inventory.27 The Brief Pain Inventory provides scores for
pain intensity (range = 0–10) and pain interference (range
= 0–10). A minimum of 3 for pain intensity was re-
quired for participation. Participants also completed the
Fibromyalgia Assessment Form46 that yields a wide-
spread pain index (range = 0–19) and a symptom severity
score (range = 0–12). Finally, participants completed a
clinician-guided Mini International Neuropsychiatric
Interview,37 and were excluded if meeting clinician cri-
teria for major depressive disorder. All selected screening
tools are commonly used in the pain literature and have
shown acceptable reliability and validity.
Sample Size
Sample size was based on a minimal correlation of in-
terest of r = .3 and desired power of 95%. With a P value
threshold of .05, 25 repeated measures per individual,
and assumed repeated measures correlation of .5, 8 in-
dividuals would be needed to achieve 95% power.
Although our main analyses (see the Statistical Analy-
ses section) examined correlations in participant-nested
data, the power analyses provided an approximation of
required sample size. However, some features of the ac-
quired data (for example, autocorrelation) were not
accounted for in the sample size calculation, because
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power calculators for linear mixed models are not ad-
equately developed at this time.
Study Procedures
The study was a 6-week observational project, includ-
ing a 2-week baseline period followed by a 25-day daily
sample collection period. Immediately after the on-site
screening, participants started an observational base-
line period of 2 weeks. Daily symptoms were obtained
through a questionnaire delivered on Android-based
tablets running Qualtrics Survey Software (Qualtrics; Provo,
UT). Fibromyalgia pain severity was rated on a 0 to 100
visual and numerical scale with the question, “Overall,
how severe has your pain been today?” The far left of
the scale was anchored at “no pain” and the far right
anchored at “severe pain.” The daily questionnaire, com-
pleted at the end of the day, also contained items to
measure fatigue, mood, stress, sleep quality, physical ac-
tivity, and gastrointestinal symptoms. Those items were
not analyzed in this study. To reduce bias, participants
were not informed of the exact blood tests to be con-
ducted, and were not informed of the study hypotheses
until their completion of the protocol. During the study
period, participants were asked to avoid taking over-
the-counter analgesics, and to report any such use on the
daily questionnaire.
At the end of the baseline period, participants began
the daily blood draws. Laboratory visits were scheduled
for 25 consecutive days, including weekends. Appoint-
ments were held at the same time each day for the
individual, to minimize diurnal effects. Trained phleboto-
mists or research nurses drew 8 mL of blood with a 21-
to 23-gauge butterfly needle into serum separating tubes
(BD Vacutainer; Becton, Dickinson and Co, Franklin Lakes,
NJ). Using standard processing protocols, the blood
samples were kept at room temperature for 30 minutes
and then centrifuged at 1,300g for 15 minutes. The serum
layer was extracted and stored at -80°C. Throughout this
phase of the study, participants continued to complete
their daily pain reports. Participants were paid $50 for
each laboratory visit.
Sample Processing
Sex hormone concentrations were analyzed in serum
samples by the Metabolism Core at UAB, under the di-
rection of Dr. Barbara Gower. Total progesterone,
estradiol, and testosterone assays were conducted using
standard assay manufacturer protocols using an auto-
mated immunoassay analyzer (AIA-900; Tosoh Bioscience,
South San Francisco, CA), using the fluorescent enzyme
immunoassay method. Cortisol was also assayed in sera
samples using the same procedures. Laboratory techni-
cians were blinded to the study protocol.
Statistical Analyses
The 3 primary hypotheses were tested in a single, mul-
tivariate linear mixed model using SPSS version 24 (IBM
Corp, Armonk, NY), a restricted maximum likelihood
estimation procedure, and an autoregressive covari-
ance structure. Daily pain was the dependent variable.
Daily values of all 3 sex hormones (estradiol, testoster-
one, progesterone, and cortisol) were entered as
independent predictors. Data were nested according to
subject, with study day as the repeated-measures index
variable. All time-series data were person-centered (z-
scored) to remove the influence of between-subject
differences.
A Bonferroni adjustment was used for the 3 main
predictors to hold the overall chance of error to .05,
yielding a P value threshold of .017. The decision to
use a correction for multiple comparisons was made after
data collection and was therefore not accounted for in
the sample size calculation performed before data
collection.
Results
One individual was excluded at baseline because of ab-
normally elevated erythrocyte sedimentation rate values.
Eight individuals, aged 33 ± 8.6 years, met all criteria for
participation. Average depression symptom severity (6.9,
SD = 3.9) was in the normal range, as was anxiety (5.6,
SD = 2.4). The group showed moderately high pain se-
verity (6.8, SD = 3.8) and moderate pain interference (4.6,
SD = 1.5). The Fibromyalgia Assessment Form wide-
spread pain index was 10.3 (SD = 4.6) and the
somatosensory scale was 9.6 (SD = 2.5). No participants
met criteria for major depressive disorder in the Mini In-
ternational Neuropsychiatric Interview. One participant
took pregabalin for the duration of the study, and 1 took
gabapentin (Table 1). No participants reported use of over-
the-counter analgesics or anti-inflammatories during the
study. Table 1 shows additional demographic informa-
tion on the final study cohort. On visual review of
individual-level sex hormone plots, all participants showed
the expected peaks of estrogen and progesterone, sug-
gesting normal menstrual cycles. Across the 25-day study
period, average progesterone was 4.11 ± 5.64 ng/mL, es-
tradiol 92.56 ± 65.62 pg/mL, and testosterone 42.36 ±
17.49 ng/mL. The pain level across all days was 56.49 ±
26.54. Average cortisol was 12.92 ± 6.4 µg/dL. Hormone
and pain levels across time are shown for the entire
sample in Fig 1.
Hormone data were not obtained for 6 of 200 visits
(3%) because of missed laboratory visits. These days were
treated as missing values and were not imputed. There
were no missing pain reports.
The interassay coefficients of variation were: proges-
terone = 2.26%, estradiol = 1.42%, testosterone = 7.49%,
and cortisol = 2.46%. Intra-assay coefficients of varia-
tion were 1.04%, 2.31%, 11.05%, and 5.19%, respectively.
Minimum detection values were .10 ng/mL, 25.0 pg/mL,
10 ng/mL, and .2 µg/dL, respectively. All samples pro-
vided detectable levels of hormones.
There was a significant and inverse relationship
between pain severity and progesterone (F = -9.76,
P = .002) as well as testosterone (F = -6.01, P = .015). Serum
levels of estradiol were not associated with pain (F = .36,
P = .551). Because previous research has shown a positive
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relationship between cortisol and fibromyalgia pain,15 we
also included main effects for cortisol, which was not sig-
nificant (F = .23, P = .633). The strongest relationship, on
the basis of statistical indices, was found between pro-
gesterone and pain, and Fig 2 shows individual plots for
each participant.
Post hoc analyses were performed to examine pos-
sible interactions between cortisol and sex hormones.
Interaction terms were entered into the same linear mixed
model. Cortisol interacted with progesterone to influ-
ence pain (F = -11.20, P = .001). To explore the nature of
the interaction, cortisol was split into tertiles (low,
medium, and high). Progesterone was not correlated with
pain during low cortisol (r = .10, P = .454) or during mod-
erate cortisol (r = -.22, P = .096), but was during times of
high cortisol (r = -.45, P = .0004). Fig 3 shows the inter-
action of cortisol and progesterone on pain. Pain was
greatest on days when progesterone was low and cor-
tisol was high. The correlation of progesterone and
pain was not related to participants’ average cortisol over
the 25 days (r = -.33, P = .420). Significant interactions
were not identified between cortisol and other sex
hormones.
As a post hoc analysis, we further tested the relation-
ship between progesterone and pain. A linear mixed
model was constructed to determine if pain differences
between high and low progesterone phases were sta-
tistically and clinically significant. We contrasted average
pain in the 3-day progesterone nadir to the 3-day pro-
gesterone peak. When progesterone was lowest, average
pain was 66.5. When progesterone was highest, pain was
rated as 50.4. This 25.6% decrease in pain was statisti-
cally significant (F = 9.1, P = .005).
Discussion
In this study, we tested if the sex hormones estradiol,
progesterone, and testosterone are associated with daily
pain severity in women with fibromyalgia. We found that
progesterone and testosterone, but not estradiol, were
associated with day-to-day changes in self-reported pain
severity. Progesterone and testosterone were inversely
associated with pain, with peaks of those hormones oc-
curring on days with lower reported pain. Self-reported
Table 1. Demographic Characteristics and Screening Blood Test Values
PARTICIPANT AGE RACE PAIN FREE T3 FREE T4 TSH VIT-D HSCRP ESR RBC WBC ANALGESICS
1 39 Caucasian 9 3.2 1.15 1.23 14.6 1.47 10 4.56 9.08
2 37 Caucasian 4 86 (Total) 1.3 .99 27.8 .86 6 4.24 8.38
3 21 Caucasian 6 2.8 1.23 .60 55.9 .9 0 4.42 2.67 Pregabalin
4 46 Caucasian 3 2.1 .77 2.10 29.3 3.66 14 4.55 8.35
5 27 Asian 7 3.4 11.3 (Total) 3.00 6.3 .32 4 5.11 6.09
6 24 Caucasian 5 90 (Total) 6.3 .92 16.7 .45 5 4.41 6.84
7 26 African American 8 3.0 1.03 .73 15.3 <.2 10 4.69 4.41
8 39 African American 9 88 (Total) .86 1.59 15.2 34.2 36 4.22 8.22 Gabapentin
Abbreviations: T3, tri-iodothyronine (nanograms per deciliter; free unless indicated as total); T4, thyroxine (nanograms per deciliter; free unless indicated as total);
TSH, thyroid stimulating hormone (international units per milliliter); Vit-D, vitamin D (nanograms per milliliter); hsCRP, high sensitivity C-reactive protein (milligrams
per liter); ESR, erythrocyte sedimentation rate (millimeters per hour); RBC, red blood cell count (million per microliter); WBC, white blood cell count (thousand per
microliter).
NOTE. No participants had detectable levels of antinuclear antibody or rheumatoid factor (not shown). Pain values were collected from a single-item measure,
“How would you rate your average daily pain on a scale from 0 (no pain at all) to 10 (worse possible pain)?”
Figure 1. Relationship between progesterone (green), testosterone (blue), estradiol (gray), and pain (red) over 25 days in 8 women
with fibromyalgia. Individuals began their participation at different points of their cycle, therefore time courses have been shifted
to allow representation of group averages. The “day” index variable was shifted so that the first estradiol peak occurred in the
same time period for all participants. The fit was confirmed by observing that the progesterone peak also was temporally aligned
for all participants. All y-axis values have been subject-centered (z-scored) to allow variables to be plotted on the same scale, and
represent SDs from the subject mean.
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fibromyalgia pain was lowest in the midluteal phase,
corresponding to high progesterone and moderate es-
tradiol and testosterone levels. Pain was highest during
the menstrual phase, when all sex hormones are at low
levels. These results are consistent with previous reports
that women with chronic pain show higher pain sensi-
tivity in the menstrual phase.18
Our results largely agree with previous research.
Decades of research have shown that sex hormones affect
pain processing in animal models.13,39,41,44 Not only do
rodent and other animal models show greater pain sen-
sitivity in the female, but that sensitivity can be reliably
affected by experimental manipulation of sex hormones.23
Large studies of humans have similarly identified rela-
tionships between sex hormones and pain. de Kruijf and
colleagues reported in a large, population study of
9,717 participants that lower levels of sex hormones
(estrogen, testosterone, androstenedione, and 17-
hydroxyprogesterone) were associated with the prevalence
and incidence of chronic musculoskeletal pain.10 Another
cross-sectional study of 188 women using hormonal con-
traceptives reported that progestin-only contraceptive
users had a higher pain tolerance than participants re-
ceiving a combined hormonal contraceptive.24 Our results
1                              14 25 1                              14 25 1                              14 25 1                              14 25






Figure 2. Relationship between progesterone and pain in all 8 participants over 25 days (x-axis). The green line represents pro-
gesterone and the blue line represents pain. Progesterone and pain have been subject-centered (z-scored) to allow plotting on
the same scale. Time courses have been shifted to reflect the expected menstrual cycle, so that the progesterone peak occurs at
the end of each participants’ time series.
Figure 3. Progesterone and cortisol interaction predicts fibromyalgia pain. Person-centered cortisol (x-axis) and progesterone (x-
axis bin) have been split into low, average, and high tertiles. Person-centered pain is on the y-axis. Pain is highest when progesterone
is low (left bin) while cortisol is high (red column).
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do diverge from a previous study29 examining sex
hormones and fibromyalgia pain in 74 women complet-
ing 3 laboratory sessions across a menstrual cycle. In that
study, no significant relationship between sex hormones
and pain threshold or tolerance was found. It is pos-
sible that our use of 25 consecutive days of sampling gave
us greater power to detect mild to moderate relation-
ships between hormones and pain.
We also observed that sex hormones may interact with
other hormones to influence pain. A low progesterone
level was associated with higher pain level, but particu-
larly so during times of high cortisol (Fig 3). There are
likely many more interactions of interest that could be
further explored with this research model, including
adrenal and thyroid hormones, neuropeptides, neu-
rotransmitters, cytokines, and other factors. Using the
same daily sampling approach, we have previously re-
ported inflammatory and hormonal drivers of fatigue in
chronic fatigue syndrome.42 Although that study was con-
ducted in chronic fatigue syndrome participants, many
such individuals also meet criteria for fibromyalgia.38 It
is possible that an optimized set of analytes could predict
most pain fluctuations in fibromyalgia. Comprehen-
sively measuring chemistry related to pain is outside the
scope of this pilot study, but is of great interest for future
research. Daily sampling, although intensive and poten-
tially burdensome on participants, can provide unique
data to explore psychophysiological relationships.
Although we found significant effects for progester-
one and testosterone, we did not observe an effect for
estradiol. It is possible that the effects of estradiol, which
is preceded by an increase of testosterone and co-
occurs with an increase of progesterone, cannot easily
be temporally separated from the effects of other hor-
mones. As noted in the introductory section, the
relationship between estrogens and pain is complex and
unresolved, showing proalgesic as well as analgesic prop-
erties in the literature. Polymorphisms in estrogen
receptors likely need to be closely studied15 as well as the
differential effects of the various estrogen metabolites.33
It is also possible that the effect of sex hormones on pain
will differ between men and women.
The change of pain associated with sex hormones may
be clinically significant, because the progesterone peak
is associatedwith a 25.6% lower pain severity. It is unknown
if the results from this and other studies indicate that ma-
nipulation of sex hormones may be used to modulate
fibromyalgia pain. There is little experimental evidence
in chronic pain conditions on this topic, and exogenous
modulators of sex hormones could act differently than
normally cycling hormones. We noted cases in which sex
hormones were administered systemically45 or locally32 to
reduce pain and/or inflammation, and the use of sex hor-
mones in treating autoimmune pain disorders is still a
topic of interest.19 Effects of administered sex hormones
on pain have also been studied in the context of trans-
sexual individuals receiving hormone treatment. In Aloisi
and colleagues’ study3 assessing varied chronic pain con-
ditions, 55% of female-to-male trans-sexual individuals
with chronic pain reported a reduction of pain after tes-
tosterone treatment (none reported increased pain). In
male-to-female individuals receiving estrogen, 23%
reported initiation of chronic pain after estrogen and
antiandrogen therapy andanother 18%reported agreater
sensitivity to pain. This evidence collectively suggests that
testosterone can reduce pain severity.
A few limitations should be discussed. One limitation
of the study was its observational approach. Although
animal studies show that sex hormones have an effect
on nociception and pain behavior, very little similar ex-
perimental research has been conducted in humans,
especially in the context of chronic pain.14 Because all
women showed the canonical sex hormone cycle, it is
more likely that sex hormones influenced pain rather than
vice-versa, but this study cannot definitively determine
causation. It is also important to note that we did not
observe any dysregulated sex hormones in this small
sample. Consistent with previous studies,1,6,29,36 sex hor-
mones appear normal in women with fibromyalgia. There
is no evidence that sex hormones are part of fibromyalgia
pathology. Rather, sex hormones may be a moderator of
pain in fibromyalgia. These effects are likely not unique
to fibromyalgia, and could be studied in other chronic
pain conditions.
The subject size of 8 women is limited. Although the
study involves 200 independent laboratory visits, and
therefore sufficient statistical power for our tests, using
only 8 subjects means we cannot confidentially gener-
alize results to the entire fibromyalgia population.
Replication in an independent and larger sample will be
required. Collecting samples over 28 days instead of 25
days would also have been preferable, allowing more
complete coverage of a full menstrual cycle. Collection
was stopped at 25 days to avoid requiring laboratory visits
over a fourth weekend, which is particularly burden-
some for participants and staff. It is also possible that more
sensitive or comprehensive measures of the primary pain
outcome could be used, such as the pain intensity scale
of the Brief Pain Inventory. Our single-item pain sever-
ity marker does not have demonstrated reliability and
validity. The study may have also been strengthened by
including a healthy control group. However, healthy
women who have completed self-report measures in our
protocol show insufficient variability of pain (often re-
porting 0 pain for all days) to allow correlational analyses
between sex hormones and pain to be computed. Another
limitation is that participant #8 returned a C-reactive
protein result of 34.2 mg/L at baseline, which could in-
dicate an inflammatory disorder or infection. The
individual did not meet exclusionary criteria for the study
and was retained in the analyses. There are likely im-
portant individual differences in the relationship between
sex hormones and pain, especially because several par-
ticipants showed no observable relationship between their
hormone levels and pain. With a small sample size, we
cannot account for those individual differences, and will
explore possible fibromyalgia subgroups in future studies.
Conclusions
There are several additional questions regarding sex
hormones and pain that could be answered with future
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applications of this study design. We are interested to
know if sex hormones predict pain levels in postmeno-
pausal women, and women taking oral contraceptives.
It would also be interesting to examine other pain
syndromes that can exhibit day-to-day fluctuations in se-
verity. We should also determine if sex hormones can drive
pain severity in men with fibromyalgia. Future studies may
also examine the relationship of sex hormones on other
aspects of fibromyalgia, such as fatigue and cognitive
symptoms. We conclude that this research adds to the
strong literature showing a relationship between sex hor-
mones and pain,4 and suggest that those relationships
have real-world consequences for individuals with chronic
pain disorders. Sex hormones may be an important target
for successfully managing some chronic pain conditions.
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